Inflammatory Bowel Diseases (IBD) Drug Market Report to 2031
Forecasts by Drug Class (Biologics, Aminosalicylates, Corticosteroids, Antibiotics, Immunomodulators, Others), by Indication (Crohn’s Disease, Ulcerative Colitis), by Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy) AND Regional and Leading National Market Analysis PLUS Analysis of Leading IBD Drug Companies AND COVID-19 Recovery Scenarios
Inflammatory Bowel Disease Drugs Market – reveals latest opportunities, trends, projected revenues, and competitive landscape. Read on to determine how you can exploit the impending business opportunities emerging in this sector along with detailed COVID-19 recovery scenarios.
Global inflammatory bowel disease drugs market is projected to reach a market value of US$xxbillion by 2031 with a lucrative CAGR during the forecast period. The growing prevalence of inflammatory bowel disease including Crohn’s disease and ulcerative colitis and growing investment in R&D by pharmaceutical companies are major factor that drives the demand for IBD drugs. Some other key factors that propel the market growth are the growing adoption of drugs for inflammatory bowel disease treatment and maintenance therapy; rising awareness for Crohn’s disease and ulcerative colitis in developing countries; and technological advancements. In addition, the COVID-19 pandemic has a significant impact on the IBD drugs market.
Visiongain’s report shows you the potential revenue streams to 2031, assessing the different segments, major players, qualitative analysis, opportunities trends, and business prospects in the inflammatory bowel disease drugs industry.
How this report will benefit you Visiongain’s 330+ page report provides 199 tables and 147 charts/graphs. Our new study is envisioned for anyone requiring commercial in-depth analyses for the global IBD drugs market along with detailed segment analysis in the market. Our new study assists you to evaluate the overall global and regional market for IBD drugs. Get the financial analysis of the overall market and different segments including drug class, indication, patient demographics, end-user, and distribution channel and capture higher market share. High opportunity remains in this fast-growing inflammatory bowel disease drugs market. See how to use the existing and upcoming opportunities in this market to gain revenue benefits in the near future. Moreover, the report would help you to improve your strategic decision-making, allows you to frame growth strategies, reinforce the analysis of other market players, and maximise the productivity of the company.
Forecasts to 2031 and other analyses reveal the commercial prospects • Our new study provides you with revenue forecast by different segments including drug class, indication, and distribution channel to 2031 • It also includes growth rates for different 4 regional markets along with 11 countries and COVID-19 impact analysis on each market • The profiles of the top 13 companies are very descriptive and comprehensive data including company snapshot, overview, commercial developments, company market shares, and detailed financial analysis with revenue and other financials • The COVID-19 has a positive impact on the IBD drugs industry and the report includes detailed analysis and invaluable insight into how COVID-19 will affect the industry.
Discover sales forecasts for the global and regional market forecasts from 2021-2031 Along with revenue prediction for the overall global inflammatory bowel disease market, there is segmentation by region for 4 regional markets including the U.S., Japan, Europe5, BRIC, and RoW and 11 major countries.
Global Inflammatory Bowel Disease Drugs Market Revenue and Growth Forecasts from 2021 to 2031 By Drug Class • Biologics • Aminosalicylates • Corticosteroids • Antibiotics • Immunomodulators • Others
Global Inflammatory Bowel Disease Drugs Market Revenue and Growth Forecasts from 2021 to 2031 By Indication • Crohn’s Disease • Ulcerative Colitis
Global Inflammatory Bowel Disease Drugs Market Revenue and Growth Forecasts from 2021 to 2031 By Distribution Channel • Hospital Pharmacy • Retail Pharmacy • Online Pharmacy
Regional market revenue and growth forecasts from 2021 to 2031:
Detailed profiles of 13 leading companies that are operating in the market The report includes profiles of 13 major companies involved in the IBD drugs market. The companies profiled in this report include: AbbVie, Janssen Biotech, Allergan plc., Takeda Pharmaceuticals, Pfizer Inc., Novartis AG, UCB Pharma S.A., Biogen Inc., Gilead Sciences, Inc., F. Hoffmann-La Roche AG, Celgene Corporation, Celltrion Corporation, and Ferring B.V.
Find qualitative and quantitative analyses with independent predictions. Receive information that only our report contains, staying informed with this invaluable business intelligence.
In summary, our 330+ page report delivers you with the following knowledge: • Revenue forecasts from 2021 to 2031 for the global IBD drugs market and subsegments (by drug class, indication, distribution channel, and region)– discover the industry’s prospects, finding the most lucrative areas for investments and revenue generation • Detailed profiles of top 13 IBD drugs manufacturers, with financial overviews • Revenue forecasts from 2021 to 2031 for 4 regional markets – See forecasts for the IBD drugs market in the U.S., Japan, Europe5, BRIC, and RoW.
Information found nowhere else With this new and exclusive report, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your investment, research, analyses, and decisions. Visiongain’s study is for everybody needing commercial analyses for the IBD drugs market and detailed analysis of COVID-19 impact. You will get the most recent data, opportunities, trends, and predictions.
The Inflammatory Bowel Disease Drugs Market Forecast 2021-2031 will be of value to anyone who wants to better understand the market and its various segments. It would be valuable for companies that desire to better understand the part of the industry they are involved in, or those coveting to expand or enter into a different regional market or to understand strategic analysis of leading companies of the IBD drugs industry.
Buy our report today Inflammatory Bowel Diseases (IBD) Drug Market Report to 2031: Forecasts by Drug Class (Biologics, Aminosalicylates, Corticosteroids, Antibiotics, Immunomodulators, Others), by Indication (Crohn’s Disease, Ulcerative Colitis), by Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy) AND Regional and Leading National Market Analysis PLUS Analysis of Leading IBD Drug Companies AND COVID-19 Recovery Scenarios. Avoid missing out by staying informed – order our report now.
Visiongain is a trading partner with the US Federal Government CCR Ref number: KD4R6
Do you have any custom requirements we can help you with? Any need for a specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: sara.peerun@visiongain.com
1. Report Overview 1.1. World Inflammatory Bowel Disease Drugs (IBD) Market: Overview of Findings 1.2. Global Inflammatory Bowel Disease Drugs Market Segmentation 1.3. Why You Should Read This Report 1.1 Main Questions Covered in the Analysis 1.4. What This Report Delivers 1.5. Key Questions Answered By This Analytical Report Include: 1.6. Who is This Report For? 1.7. Methodology 1.1.1 Primary Research 1.1.2 Secondary Research 1.1.3 Market Evaluation and Forecasting Methods 1.8. COVID-19 Impact: Recovery Scenarios 1.9. Frequently Asked Questions (FAQs) 1.10. Associated Visiongain Reports 1.11. About Visiongain
2 Executive Summary
3 Introduction to the Inflammatory Bowel Disease Drug Market 3.1 What is Inflammatory Bowel Disease (IBD)? 3.2 Classification of IBD 3.3 Symptoms and Diagnosis of IBD 3.4 Multifactorial Causes of IBD 3.5 How common is IBD? 3.6 What Are the Treatment Options for IBD? 3.6.1 Aminosalicylates – The Most Common Therapy 3.6.2 Antibiotics – Supporting Evidences 3.6.3 Corticosteroids – growth is majorly driven by Uceris 3.6.4 Immunomodulators – Slow to Act? 3.6.5 Biologics – Not Cost-effective? 3.7 Treatment Goals for IBD – Treat-to-Target Approach? 3.8 Treatment Algorithm 3.9 Management of Inflammatory Bowel Disease – 2020
4 Market Dynamics 4.1 Drivers Analysis – Inflammatory Bowel Disease Drugs Market 4.1.1 Increasing Disease Incidence in Most National Markets 4.1.2 Better Diagnosis of IBD 4.1.3 Delivery Systems Improve Existing Drugs of IBD 4.2 Opportunity Analysis – Inflammatory Bowel Disease Drugs Market 4.2.1 Biological Drugs – Driving the Market Significantly 4.2.2 Socioeconomic Costs of IBD 4.3 Restrains Analysis – Inflammatory Bowel Disease Drugs Market 4.3.1 Lack of Understanding of Disease Aetiology 4.3.2 Compliance – Frequent Dosing is Inconvenient 4.3.3 Limitations of Biologics – Side Effect Profiles 4.4 Challenges Analysis – Inflammatory Bowel Disease Drugs Market 4.4.1 The Possible Development of Alternative Treatments 4.4.2 Surgery – Treatment for Recalcitrant IBD 4.4.3 Health Care Cost Containment 4.5 Porter’s Five Forces Analysis – Inflammatory Bowel Disease Drugs Market 4.5.1 Bargaining Power of Supplier: Low 4.5.2 Bargaining Power of Buyer: Moderate 4.5.3 Competitive Rivalry: High 4.5.4 Threat of New Entrants: High 4.5.5 Threat of Substitutes: High 4.6 SWOT Analysis – Inflammatory Bowel Disease Drugs Market 4.6.1 Strengths 4.6.2 Weaknesses 4.6.3 Opportunities 4.6.4 Threats 4.7 PEST Analysis – Inflammatory Bowel Disease Drugs Market 4.7.1 Political 4.7.2 Economical 4.7.3 Social 4.7.4 Technological
5 Global Inflammatory Bowel Diseases Drug Market, 2021-2031 5.1 Global Inflammatory Bowel Disease Drugs Market: COVID-19 Recovery Forecasts (V, U, W, L) 2021-2031 5.1.1 "V" shaped Recovery - Rapid Decline - Sharp Borrow -Rapid Recovery 5.1.2 "U" Shaped Recovery -Rapid Decline Early Then Slow - Gradual at the Bottom - Slow Recovery at First - Faster Recovery Later On 5.1.3 "W" Shaped Recovery -Rapid Decline - Rapid Recovery- Return of Virus - Another Sharp Decline -Recovery 5.1.4 "L" Shaped Recovery - Rapid Decline - Then Slow Growth
6 Global Inflammatory Bowel Diseases Drug Market by Indication, 2021-2031 6.1 Global Inflammatory Bowel Disease Drugs Market for Crohn’s Disease Segment: Revenue Forecast 2021-2031 6.1.1 Recovery Forecasts (V, U, W, L) 6.2 Global Inflammatory Bowel Disease Drugs Market for Ulcerative Colitis Segment: Revenue Forecast 2021-2031 6.2.1 Recovery Forecasts (V, U, W, L)
7 Global Inflammatory Bowel Disease Drugs Market Size Forecast 2021-2031 by Drug Class 7.1 Global Inflammatory Bowel Disease Drugs Market for Biologics Segment: Revenue Forecast 2021-2031 7.2 Biologic Therapies Forecast 2021-2031 – Largest Revenue Grossing Segment 7.2.1 Recovery Forecasts (V,U, W, L) 7.3 Aminosalicylates Forecast 2021-2031: The Steady Growth 7.3.1 Recovery Forecasts (V,U, W, L) 7.4 Corticosteroids Forecast 2021-2031: Rescue therapies 7.4.1 Recovery Forecasts (V,U, W, L) 7.5 Antibiotics Forecast 2021-2031: Growing Despite Challenges 7.5.1 Recovery Forecasts (V,U, W, L) 7.6 Immunomodulators Forecast 2021-2031 – Will Grow at Moderate Pace 7.6.1 Recovery Forecasts (V,U, W, L) 7.7 Other Drug Classes Segment Forecast 2021-2031 – Will Grow at a Significant Rate 7.7.1 Recovery Forecasts (V,U, W, L)
9 Leading National Markets: Sales Outlooks, 2021- 2031 9.1 Global Inflammatory Bowel Disease Drugs Market Overview: Regional Distribution, 2021- 2031 9.2 Inflammatory Bowel Disease Drugs - Leading National Markets 2020 9.3 The US IBD Drugs Market, 2021-2031 – The World Leader in the Inflammatory Bowel Disease Drugs Market 9.3.1 COVID-19 Market Recovery for US Inflammatory Bowel Disease Drugs Market: "V" shaped Recovery 2021- 2031 9.3.2 COVID-19 Market Recovery for US Inflammatory Bowel Disease Drugs Market: "U" shaped Recovery 2021- 2031 9.3.3 COVID-19 Market Recovery for US Inflammatory Bowel Disease Drugs Market: "W" shaped Recovery 2021 – 2031 9.3.4 COVID-19 Market Recovery for US Inflammatory Bowel Disease Drugs Market: "L" shaped Recovery 2021- 2031 9.3.5 U.S. IBD Drugs Market By Drug Class, 2021-2031 9.3.6 U.S. IBD Drugs Market By Indication, 2021-2031 9.3.7 U.S. IBD Drugs Market By Distribution Channel, 2021-2031 9.4 The Japanese IBD Drugs Market, 2021-2031- Developed Healthcare Infrastructure is Expected to Boost the Market Growth 9.4.1 COVID-19 Market Recovery for Japan Inflammatory Bowel Disease Drugs Market: "V" shaped Recovery 2021- 2031 9.4.2 COVID-19 Market Recovery for Japan Inflammatory Bowel Disease Drugs Market: "U" shaped Recovery 2021- 2031 9.4.3 COVID-19 Market Recovery for Japan Inflammatory Bowel Disease Drugs Market: "W" shaped Recovery 2021 – 2031 9.4.4 COVID-19 Market Recovery for Japan Inflammatory Bowel Disease Drugs Market: "L" shaped Recovery 2021- 2031 9.4.5 Japan IBD Drugs Market By Drug Class, 2021-2031 9.4.6 Japan IBD Drugs Market By Indication, 2021-2031 9.4.7 Japan IBD Drugs Market By Distribution Channel, 2021-2031 9.5 The EU5 IBD Drugs Market, 2021-2031 9.5.1 COVID-19 Market Recovery for EU5 Inflammatory Bowel Disease Drugs Market: "V" shaped Recovery 2021- 2031 9.5.2 COVID-19 Market Recovery for EU5 Inflammatory Bowel Disease Drugs Market: "U" shaped Recovery 2021- 2031 9.5.3 COVID-19 Market Recovery for EU5 Inflammatory Bowel Disease Drugs Market: "W" shaped Recovery 2021 – 2031 9.5.4 COVID-19 Market Recovery for EU5 Inflammatory Bowel Disease Drugs Market: "L" shaped Recovery 2021- 2031 9.5.5 EU5 IBD Drugs Market By Drug Class, 2021-2031 9.5.6 EU5 IBD Drugs Market By Indication, 2021-2031 9.5.7 EU5 IBD Drugs Market By Distribution Channel, 2021-2031 9.5.8 Germany Inflammatory Bowel Disease Drugs Market, 2021- 2031 9.5.8.1 Germany Accounted For The Largest Revenue Share In The EU5 Inflammatory Bowel Disease Drugs Market 9.5.8.2 Presence of Well-Established Healthcare Infrastructure 9.5.9 UK Inflammatory Bowel Disease Drugs Market, 2021- 2031 9.5.9.1 Increasing Prevalence Of IBD In The UK Is Driving The Demand Of Advanced Drugs 9.5.9.2 Growing Awareness For The IBD Among People 9.5.10 France Inflammatory Bowel Disease Drugs Market, 2021- 2031 9.5.10.1 Availability Of Advanced Healthcare In This Region Will Propel The Demand For Inflammatory Bowel Disease Drugs 9.5.10.2 Growing Research Funding Is Boosting The French Market 9.5.11 Italy Inflammatory Bowel Disease Drugs Market, 2021- 2031 9.5.11.1 One Of The Fastest Growing Market In EU5 Region 9.5.11.2 Growing Number Of Product Launches Will Boost The Regional Market Growth 9.5.12 Spain Inflammatory Bowel Disease Drugs Market, 2021- 2031 9.5.12.1 Rising Prevalence Of IBD In This Region Will Drive The Spain Market Growth 9.5.12.2 Rising Number Healthcare Awareness Programs By The Government 9.6 The BRIC IBD Drugs Market, 2021-2031 – Fastest Growing Region in the Global IBD Market 9.6.1 COVID-19 Market Recovery for BRIC Inflammatory Bowel Disease Drugs Market: "V" shaped Recovery 2021- 2031 9.6.2 COVID-19 Market Recovery for BRIC Inflammatory Bowel Disease Drugs Market: "U" shaped Recovery 2021- 2031 9.6.3 COVID-19 Market Recovery for BRIC Inflammatory Bowel Disease Drugs Market: "W" shaped Recovery 2021 – 2031 9.6.4 COVID-19 Market Recovery for BRIC Inflammatory Bowel Disease Drugs Market: "L" shaped Recovery 2021- 2031 9.6.5 BRIC IBD Drugs Market By Drug Class, 2021-2031 9.6.6 BRIC IBD Drugs Market By Indication, 2021-2031 9.6.7 BRIC IBD Drugs Market By Distribution Channel, 2021-2031 9.6.8 Brazil Inflammatory Bowel Disease Drugs Market, 2021- 2031 9.6.8.1 Developing Healthcare Infrastructure Is Expected To Have Positive Impact On The Regional Market Growth 9.6.8.2 Medical Tourism In Brazil Will Have Positive Impact On The Regional Market Growth 9.6.9 Russia Inflammatory Bowel Disease Drugs Market, 2021- 2031 9.6.9.1 Increasing investment by the government on healthcare infrastructure is a major factor that will boost the market growth 9.6.9.2 Rising Awareness For IBD Among Healthcare Professionals And People 9.6.10 India Inflammatory Bowel Disease Drugs Market, 2021- 2031 9.6.10.1 One of the fastest growing market in BRIC region 9.6.10.2 Developing Infrastructure In India 9.6.11 China Inflammatory Bowel Disease Drugs Market, 2021- 2031 9.6.11.1 Fastest Growing Region In The Global IBD Market 9.6.11.2 Presence Of Leading Manufacturers In This Region
10 The R&D Pipeline for Inflammatory Bowel Diseases 10.1 Top Marketed and pipeline products – Launch dates and Patent expiry 10.2 Interleukin (IL) Inhibitors – One of the Main Areas of Innovation 10.2.1 STI-0529, Sublimity Therapeutics (formerly CyCol, Sigmoid Pharma) 10.2.2 PF-04236921 (Pfizer) 10.2.3 QAX 576 (Novartis) 10.2.4 TNF Kinoid (Neovacs) 10.2.5 Vidofludimus (4SC) – Suspended 10.2.6 Stelara (Ustekinumab, CNTO 1275, Janssen Biotech) 10.2.7 Entyvio (Vedolizumab, Takeda) 10.2.8 Risankizumab, Abbvie and Boehringer Ingelheim 10.2.9 Brazikumab, Allergan (Under collaboration agreement with AstraZeneca & Amgen) 10.3 Cell-Adhesion Molecule (CAM) Inhibitors – A Promising Avenue 10.3.1 AJG 511 (Ajinomoto Pharmaceutical Co.) 10.3.2 AJM 300 (Ajinomoto Pharmaceuticals) 10.3.3 MEDI 7183/AMG 181 (AstraZeneca) 10.3.4 Etrolizumab (Roche) 10.3.5 PF-00547659 (Pfizer) 10.3.6 Alicaforsen (ISIS 2302, Atlantic Healthcare) 10.3.7 MEDI-2070/AMG 139 (AstraZeneca & Amgen) 10.4 TNF-α Inhibitors – a Specific Target 10.4.1 AVX-470 (Avaxia Biologics) 10.4.2 Ozoralizumab (ALX-0061, Ablynx) 10.5 Stem Cell Therapies – Basis for a Cure? 10.5.1 Ovasave (TxCell) 10.5.2 MultiStem (Athersys and Pfizer) 10.5.3 Prochymal (Remestemcel-L, Osiris Therapeutics) 10.5.4 Cx601 (TiGenix) 10.6 JAK Inhibitors – New Target Pathway 10.6.1 JNJ-54781532 (Janssen) 10.6.2 Xeljanz, (Tofacitinib, CP-690550, Pfizer) 10.7 Toll-like Receptor Agonists 10.7.1 BL-7040 (BioLineRX) 10.7.2 Kappaproct (InDex Pharmaceuticals) 10.8 Other Classes of Agent 10.8.1 Trichuris suis ova (CNDO-201, Coronado Biosciences) 10.8.2 GLPG0974 (Galapagos) 10.8.3 RPC1063 (Receptos/now Celgene) 10.8.4 SGX203 (Soligenix) 10.8.5 Mongersen (GED-0301, Celgene) 10.8.6 Tetomilast (OPC-6535, Otsuka) 10.8.7 Laquinimod (Active Biotech) 10.8.8 RHB-104 (RedHill Biopharma) 10.8.9 Ozanimod (Celgene) 10.8.10 GED-0301 (Celgene) 10.9 Biosimilar Candidates – Promising Competitors of Leading Biologics 10.9.1 Adalimumab Biosimilars 10.9.2 Infliximab Biosimilars
11 Leading Companies in the IBD Pharmaceuticals Market 11.1 Company Share Analysis 11.2 Strategic Developments, 2017-2020 11.3 Abbvie 11.3.1 Company Information 11.3.2 Business Overview 11.3.3 Pipeline Overview 11.3.4 Product Portfolio 11.3.5 Recent Developments, 2017-2020 11.4 Janssen Biotech 11.4.1 Company Information, 2020 11.4.2 Business Overview 11.4.3 Pipeline Overview 11.4.4 Product Portfolio 11.4.5 Recent Developments, 2017-2020 11.5 Allergan plc 11.5.1 Company Information, 2020 11.5.2 Business Overview 11.5.3 Pipeline Overview: 11.5.4 Product Portfolio 11.5.5 Recent Developments, 2017-2020 11.6 Takeda Pharmaceuticals 11.6.1 Company Information, 2020 11.6.2 Business Overview 11.6.3 Pipeline Overview 11.6.4 Product Portfolio 11.6.5 Recent Developments, 2017-2020 11.7 Pfizer 11.7.1 Company Information, 2020 11.7.2 Business Overview 11.7.3 Pipeline Overview 11.7.4 Product Portfolio 11.7.5 Recent Developments, 2017-2020 11.8 Novartis AG 11.8.1 Company Information, 2020 11.8.2 Business Overview 11.8.3 Pipeline Overview 11.8.4 Product Portfolio 11.8.5 Recent Developments, 2017-2020 11.9 UCB Pharma S.A. 11.9.1 Company Information, 2020 11.9.2 Business Overview 11.9.3 Pipeline Overview 11.9.4 Product Portfolio 11.10 Biogen Inc. 11.10.1 Company Information, 2020 11.10.2 Business Overview 11.10.3 Product Portfolio 11.11 Gilead Sciences, Inc. 11.11.1 Company Information, 2020 11.11.2 Business Overview 11.11.3 Pipeline Overview 11.11.4 Product Portfolio 11.12 Roche 11.12.1 Company Information, 2020 11.12.2 Business Overview 11.12.3 Pipeline Overview 11.12.4 Recent Developments, 2017-2020 11.13 Celgene Corporation 11.13.1 Company Information, 2020 11.13.2 Business Overview 11.13.3 Pipeline Overview 11.13.4 Product Portfolio 11.13.5 Recent Developments, 2017-2020 11.14 Celltrion Corporation 11.14.1 Company Information, 2020 11.14.2 Pipeline Overview 11.14.3 Product Portfolio 11.15 Ferring B.V. 11.15.1 Company Information, 2020 11.15.2 Business Overview 11.15.3 Product Portfolio
Companies Profiled in the Report AbbVie Allergan plc Biogen Inc. Celgene Corporation Celltrion Corporation Ferring B.V. Gilead Sciences, Inc. Janssen Biotech Novartis AG Pfizer Inc. Roche Takeda Pharmaceuticals UCB Pharma S.A.
List of Companies Mentioned in the Report 4SC Abbvie Ablynx Active Biotech Ajinomoto Allergan plc Amgen AstraZeneca Athersys Inc. Atlantic Healthcare Avaxia Biologics Biogen Inc. BiomX Ltd BiomX Ltd BioLine RX Boehringer Ingelheim Celgene Cellular Therapeutics Celgene Corporation Celltrion Corporation Centocor Coronado Biosciences CyCol Dr. Falk Pharma Ferring B.V. Galapagos Gilead Sciences, Inc. Harbor BioSciences InDex Pharmaceuticals Isis Pharmaceuticals J&J Janssen Biotech MedImmune Ltd Neovacs Novartis AG Osiris Therapeutics Otsuka Pfizer Inc. Pharmascience Inc. Receptos RedHill Biopharma Roche Scripps Research Sequella Servicio Sanitario Nazionale (SSN) Sigmoid Pharma Limited Soligenix Sublimity Therapeutics Pendopharm Takeda Pharmaceuticals TiGenix TxCell UCB Pharma S.A.
List of Organizations Mentioned in the Report Agencia Nacional de Vigiloncia Sanitaria (ANVISA) American Gastroenterological Association Centers for Disease Control and Prevention (CDC) Central Drug Standard Control Organization (CDSCO) Centre for Pharmaceutical Administration Health Sciences Authority Crohn’s and Colitis Foundation of Canada Departamento de Economia ECCO-Epicom group Economic Cooperation and Development (OECD) European Commission European Crohn’s and Colitis Organisation (ECCO) European Federation of Crohn's and Ulcerative Colitis Associations Food and Drug Administration (FDA) German Society of Gastroenterology (DGVS) Global Burden of Diseases (GBD) Japanese Ministry of Health, Labour and Welfare Medicines and Healthcare Products Regulatory Agency (MHRA) Ministry of Health of the Russian Federation Ministry of Health, Labour & Welfare (MHLW) National Institutes of Health (NIH) NCBI World Bank World Health Organization (WHO)
Download sample pages
Complete the form below to download your free sample pages for Inflammatory Bowel Diseases (IBD) Drug Market Report to 2031
High performance HPC and supercomputing technology have evolved substantially in China in the last decades, leading to extraordinary accomplishments. HPC-based...
Rising incidences of viral infection; increasing geriatric population is projected to propel the demand for anti-viral drugs; advancement in anti-viral...
Visiongain’s reports are based on comprehensive primary and secondary research. Those studies provide global market forecasts (sales by drug and class, with sub-markets and leading nations covered) and analyses of market drivers and restraints (including SWOT analysis) and current pipeline developments. To find out more about our reports methodology, please email sara.peerun@visiongain.com
“Thank you for this Gene Therapy R&D Market report and for how easy the process was. Your colleague was very helpful and the report is just right for my purpose. This is the 2nd good report from Visiongain and a good price.” Dr Luz Chapa Azuella, Mexico
Visiongain Publishes 3D Printing for Healthcare Market Report 2023-2033
The global 3D Printing for Healthcare market was valued at US$2,970.7 million in 2022 and is projected to grow at a CAGR of 23.6% during the forecast period 2023-2033.
Visiongain Publishes Clinical Trial Supply and Logistics Market for Pharma 2023-2033
The global Clinical Trial Supply and Logistics for Pharma market is valued at US$13.8 billion in 2023 and is projected to grow at a CAGR of 8.4% during the forecast period 2023-2033.
The global Anti-infective Vaccines market is valued at US$48,360.4 million in 2023 and is projected to grow at a CAGR of 6.6% during the forecast period 2023-2033.
Visiongain Pharma
Visiongain Pharma
Visiongain Pharma
